A randomized, double-blind, placebo-controlled trial of subcutaneous etanercept (p75 souble tumor necrosis factor:FC fusion protein) in the treatment of moderate to severe Crohn's disease.

被引：9

作者：

Sandborn, WJ

Hanauer, SB

Katz, S

Safdi, M

Wolf, DC

Baerg, RD

Tremaine, WJ

Johnson, T

Diehl, N

Zinsmeister, AR

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] N Shore Univ Hosp, Long Island, NY USA

[4] NYU, New York, NY USA

[5] Greater Cincinnati Gastroenterol Assoc Inc, Cincinnati, OH USA

[6] Atlanta Gastroenterol Assoc, Atlanta, GA USA

来源：

关键词：

D O I：

10.1016/S0016-5085(01)80100-1

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：A20 / A20

页数：1